FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 190 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Couple Buys Customized SUV To Give Free Rides To Critically Ill... September 11, 2019 Disease in a dish: Mini-gut organoids and the challenges of bowel... February 11, 2022 EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... October 12, 2023 Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... March 14, 2024 Load more HOT NEWS FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... Treating the Whole Person: How Cancer Centers Are Addressing Social Needs The Power of Fruits and Vegetables
